Janone inc. appoints tony giordano as chief scientific officer

Janone inc. announced the hiring of tony giordano, ph.d. to serve as its chief scientific officer. dr. giordano is janone’s new chief scientific officer and founding scientist. as chief scientific officer, dr. giordano will oversee development of the company’s recently announced pad treatment, tv1001sr including the phase 2b clinical protocol, manufacturing, and phase 2b clinical trials. in addition to his role with janone, he also serves as senior director of special projects in the innovations center at the cleveland clinic. as an experienced researcher and bioscientist, dr. giordano has held senior positions at cutting-edge biotechnology companies. as president of sulfagenix inc., he managed the completion of a phase 1 clinical study, gras affirmation and launch of medical food product. ?as chief executive officer of theravasc inc., he managed collaborations and development of a new drug formulation, tv1001sr, that janone recently licensed, and oversaw and managed the phase 1 clinical study and two-phase 2 studies. he also held senior positions at message pharmaceuticals inc., nucleonics inc., and alteris inc.
JAN Ratings Summary
JAN Quant Ranking